6-Thioguanine for Crohn's disease during pregnancy: thiopurine metabolite measurements in both mother and child

NK De Boer, R.M. van Elburg, A.J. Wilhelm, A.J. Remmink, J.M.G. van Vugt, C.J.J. Mulder, A.A. van Bodegraven, Nanne K. H. de Boer

Research output: Contribution to journalArticleAcademicpeer-review

27 Citations (Scopus)

Abstract

6-Thioguanine is used as an escape thiopurine for treating inflammatory bowel disease patients intolerant or refractory to azathioprine, 6-mercaptopurine or methotrexate. Case reports show conflicting data on the use of 6-thioguanine throughout pregnancy. The administration of the standard thiopurines is believed to be relatively safe. We describe two patients with Crohn's disease treated with low-dose 6-thioguanine during all trimesters of their pregnancies. The pregnancies resulted in two healthy infants: without congenital abnormalities, laboratory signs of myelosuppression or hepatocellular injury. Thiopurine metabolites were measured in mother and infant. Significantly lower levels of 6-thioguaninenucleotides were found in the erythrocytes of the infant compared to the mother ( ratio 1: 12). Further studies are needed to determine the clinical importance of thiopurine metabolite measurements during pregnancy in mother and child
Original languageEnglish
Pages (from-to)1374-1377
JournalScandinavian journal of gastroenterology
Volume40
Issue number11
DOIs
Publication statusPublished - 2005

Cite this